Abstract
A number of cytotoxic drugs were tested in mice for their ability to produce residual damage to the bone marrow. This was assessed by the ability of the drug to produce depletion of pluripotential stem cells and granulocytic progenitor cells persisting for at least two months after cessation of the drug. Evidence of residual damage was found after administration of mitomycin, chlorambucil and melphalan but not after nitrogen mustard, dimethyl-triazeno-imidazole-carboxamide or adriamycin. Residual damage has previously been found following busulphan and bischloro-nitrosurea and the features in common of the drugs causing residual damage suggest that the effect may require the ability to alkylate pluripotential stem cells. These experimental findings may explain a number of clinical observations in man.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
